Sphingadienes show therapeutic efficacy in neuroblastoma in vitro and in vivo by targeting the AKT signaling pathway Piming ZhaoAna E. AguilarJulie D. Saba PRECLINICAL STUDIES 16 January 2018 Pages: 743 - 754
The in vitro assessment of dipyridophenazine complexes in H-ras oncogene transformed rat embryo fibroblast 5RP7 cell line Ayse KaplanKadriye BenkliAyse Tansu Koparal PRECLINICAL STUDIES 08 January 2018 Pages: 755 - 762
PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation Songlin LiuYunhong TangWeixi Jiang PRECLINICAL STUDIES 05 March 2018 Pages: 763 - 772
SMER28 is a mTOR-independent small molecule enhancer of autophagy that protects mouse bone marrow and liver against radiotherapy Michael I. KoukourakisAlexandra GiatromanolakiAdrian L. Harris PRECLINICAL STUDIES 31 January 2018 Pages: 773 - 781
Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes Maria Eduarda Azambuja AmaralLaura Roesler NeryMaria Martha Campos PRECLINICAL STUDIES 02 February 2018 Pages: 782 - 796
Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide Ruud OerlemansCelia R. BerkersGerrit Jansen PRECLINICAL STUDIES Open access 14 February 2018 Pages: 797 - 809
Preclinical investigation of a potent geranylgeranyl diphosphate synthase inhibitor Staci L. HaneyYashpal S. ChhonkerSarah A. Holstein PRECLINICAL STUDIES 02 March 2018 Pages: 810 - 818
The concomitant use of lapatinib and paracetamol - the risk of interaction Agnieszka KarbownikEdyta SzałekEdmund Grześkowiak PRECLINICAL STUDIES Open access 20 February 2018 Pages: 819 - 827
A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer Diane A. J. van der BiessenJourik A. GietemaCarla M. L. van Herpen PHASE I STUDIES Open access 08 January 2018 Pages: 828 - 835
A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors Gentry T. KingKeith D. EatonAnthony B. El-Khoueiry PHASE I STUDIES 15 January 2018 Pages: 836 - 847
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer Andreas SchneeweissTjoung-Won Park-SimonAndrés Cervantes PHASE I STUDIES Open access 19 January 2018 Pages: 848 - 859
First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors Vicki L. KeedyHeinz-Josef LenzLuis H. Camacho PHASE I STUDIES 29 January 2018 Pages: 860 - 868
Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study Anastasios StathisIan W. FlinnM. Lia Palomba PHASE I STUDIES Open access 17 February 2018 Pages: 869 - 876
Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy Hyungwoo ChoDok Hyun YoonCheolwon Suh PHASE I STUDIES 09 March 2018 Pages: 877 - 885
A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers Aflah RoohullahAdam CooperLisa G. Horvath PHASE I STUDIES 16 May 2018 Pages: 886 - 894
Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer Amir Mehrvarz SarshekehHenry Q. XiongScott Kopetz PHASE II STUDIES 13 June 2018 Pages: 895 - 902
Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial Akira NakaoJunji UchinoMasaki Fujita PHASE II STUDIES 30 May 2018 Pages: 903 - 910
Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study Cassia Regina Guedes LealCristiane MagalhãesSérgio Setubal PHASE II STUDIES 13 June 2018 Pages: 911 - 918
Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) Paul MonkGlenn LiuJorge A. Garcia PHASE II STUDIES Open access 07 August 2018 Pages: 919 - 926
Oral Metronomic Vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer: outcome and pharmacokinetics in the real world Felice PasiniCarmen BarileMilena Gusella PHASE II STUDIES 28 June 2018 Pages: 927 - 932
Comparison of published and unpublished phase I clinical cancer trials: an analysis of the CliniclTrials.gov database D. ShepshelovichH. GoldvaserA. R. Abdul Razak REVIEW 13 December 2017 Pages: 933 - 938
Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis Akiyoshi KasugaYasuo HamamotoHiromasa Takaishi REVIEW 23 March 2018 Pages: 939 - 948
Crizotinib-induced simultaneous multiple cardiac toxicities Takuya OyakawaNao MuraokaToshiaki Takahashi SHORT REPORT 02 May 2018 Pages: 949 - 951
Successful oral desensitization with osimertinib following osimertinib-induced fever and hepatotoxicity: a case report Ryosuke HirabayashiDaichi FujimotoKeisuke Tomii SHORT REPORT 02 May 2018 Pages: 952 - 954
GLP overexpression is associated with poor prognosis in Chronic Lymphocytic Leukemia and its inhibition induces leukemic cell death Juliana Carvalho Alves-SilvaJuliana Lott de CarvalhoFelipe Saldanha-Araujo SHORT REPORT 31 May 2018 Pages: 955 - 960